Granted Patent B2

US 12,342,801 · App. 17/553,115 · Granted Jul 1, 2025

Inventors: Vera Voronina (North Bethesda, MD); Lynn Macdonald (Harrison, NY); Marine Prissette (Brooklyn, NY); Ka-Man Venus Lai (Seattle, WA); Ashok Badithe (Basking Ridge, NJ); Andrew J. Murphy (Croton-on-Hudson, NY); Gustavo Droguett (New City, NY); David Frendewey (New York, NY); Brian Zambrowicz (Sleepy Hollow, NY)

Assignee: Regeneron Pharmaceuticals, Inc.

A01K67/0278A01K67/0271A01K67/0276C07K16/00C12N9/6489C12N15/8509C12N15/90C12Y301/00C12Y304/24046A01K2207/05A01K2207/12A01K2207/15A01K2217/00A01K2217/072A01K2217/075A01K2217/15A01K2217/206A01K2227/105A01K2267/01A01K2267/02C07K2317/21C07K2317/24C07K2317/33C12N2015/8518

Abstract

Claims (43)

1. A method of generating antigen-binding proteins against a human foreign antigen of interest, comprising:

(a) making a transgenic mouse with reduced tolerance to the human foreign antigen of interest, comprising:

(i) introducing into a population of mouse one-cell stage embryos or a population of mouse embryonic stem (ES) cells:

(I) a Cas9 protein or a nucleic acid encoding a Cas9 protein;

(II) a first guide RNA or a DNA encoding the first guide RNA, wherein the first guide RNA hybridizes to a first guide RNA recognition sequence within a target genomic locus, wherein the target genomic locus comprises all or part of a gene encoding a self-antigen orthologous to the human foreign antigen of interest;

(III) a second guide RNA or a DNA encoding the second guide RNA, wherein the second guide RNA hybridizes to a second guide RNA recognition sequence within the target genomic locus;

(ii) screening the population of mouse one-cell stage embryos or the population of mouse ES cells for a modified mouse one-cell stage embryo or a modified mouse ES cell, wherein the target genomic locus is modified in a pair of corresponding first and second chromosomes to produce the modified mouse one-cell stage embryo or the modified mouse ES cell with a biallelic modification, wherein the biallelic modification comprises a biallelic deletion of all or part of the gene encoding the self-antigen, wherein expression of the self-antigen is eliminated;

(iii) producing a transgenic F0 generation mouse from the modified mouse one-cell stage embryo or the modified mouse ES cell, wherein the target genomic locus is modified in the pair of corresponding first and second chromosomes in the transgenic F0 generation mouse such that expression of the self-antigen is eliminated;

(b) immunizing the transgenic F0 generation mouse produced in step (a) with the human foreign antigen of interest,

wherein the transgenic F0 generation mouse comprises in its germline:

(i) an ectopic nucleic acid sequence encoding a mouse ADAM6 protein, wherein the mouse ADAM6 protein is functional in a male mouse;

(ii) a heavy chain locus comprising human immunoglobulin heavy chain V, D, and J gene segments, wherein the human immunoglobulin heavy chain V, D, and J gene segments are operably linked to a mouse immunoglobulin heavy chain constant region gene, wherein the mouse immunoglobulin heavy chain constant region gene is at an endogenous mouse immunoglobulin locus; and

(iii) a light chain locus comprising human immunoglobulin light chain V and J gene segments, wherein the human immunoglobulin light chain V and J gene segments are operably linked to a mouse immunoglobulin light chain constant region gene sequence,

wherein (ii) rearranges to form a heavy chain sequence comprising a human heavy chain variable region operably linked to a mouse heavy chain constant region, and (iii) rearranges to form a light chain sequence comprising a human light chain variable region operably linked to a mouse light chain constant region, and

wherein the mouse is incapable of forming an antibody that comprises a human variable region and a human constant region; and

(c) maintaining the transgenic F0 generation mouse under conditions sufficient to initiate an immune response to the human foreign antigen of interest, wherein the transgenic F0 generation mouse produces antigen-binding proteins against the human foreign antigen of interest.

2. The method of claim 1 , wherein producing the transgenic F0 generation mouse in step (a)(iii) comprises introducing the modified mouse ES cell into a host embryo and implanting the host embryo into a surrogate mother to produce the transgenic F0 generation mouse, or

wherein producing the transgenic F0 generation mouse in step (a)(iii) comprises implanting the modified mouse one-cell stage embryo into a surrogate mother to produce the transgenic F0 generation mouse.

3. The method of claim 1 , further comprising making a hybridoma from B cells isolated from the immunized transgenic F0 generation mouse.

4. The method of claim 1 , further comprising obtaining from the immunized transgenic F0 generation mouse at least one of a first nucleic acid sequence encoding an immunoglobulin heavy chain variable domain of one of the antigen-binding proteins against the human foreign antigen of interest and a second nucleic acid sequence encoding an immunoglobulin light chain variable domain of one of the antigen-binding proteins against the human foreign antigen of interest, wherein at least one of the first nucleic acid sequence and the second nucleic acid sequence are obtained from a lymphocyte of the transgenic F0 generation mouse or from a hybridoma produced from the lymphocyte.

5. The method of claim 1 , wherein the first guide RNA recognition sequence is 5′ of the second guide RNA recognition sequence in the target genomic locus, and

wherein step (a)(ii) comprises performing a retention assay to determine the copy number for at least one of a region 5′ and within about 1 kb of the first guide RNA recognition sequence and a region 3′ and within about 1 kb of the second guide RNA recognition sequence.

6. The method of claim 1 , wherein the biallelic deletion is a precise deletion without random insertions and deletions.

7. The method of claim 1 , wherein the first guide RNA recognition sequence comprises the start codon for the gene encoding the self-antigen or is within about 1,000 nucleotides of the start codon, and the second guide RNA recognition sequence comprises the stop codon for the gene encoding the self-antigen or is within about 1,000 nucleotides of the stop codon.

8. The method of claim 1 , wherein the first and second guide RNA recognition sequences are different, and each of the first and second guide RNA recognition sequences comprises the start codon for the gene encoding the self-antigen or is within about 1,000 nucleotides of the start codon.

9. The method of claim 1 , wherein the biallelic deletion is between about 0.1 kb to about 200 kb.

10. The method of claim 1 , wherein the biallelic modification comprises a biallelic disruption of the start codon of the gene encoding the self-antigen.

11. The method of claim 1 , wherein the introducing step (a)(i) further comprises introducing into the population of mouse one-cell stage embryos or the population of mouse ES cells at least one of:

(iv) a third guide RNA or a DNA encoding the third guide RNA, wherein the third guide RNA hybridizes to a third guide RNA recognition sequence within the target genomic locus; and

(v) a fourth guide RNA or a DNA encoding the fourth guide RNA, wherein the fourth guide RNA hybridizes to a fourth guide RNA recognition sequence within the target genomic locus.

12. The method of claim 1 , wherein step (a)(i) comprises introducing the nucleic acid encoding the Cas9 protein, the DNA encoding the first guide RNA, and the DNA encoding the second guide RNA into the population of mouse ES cells, wherein the nucleic acid encoding the Cas9 protein is DNA, or

wherein the Cas9 protein or the nucleic acid encoding the Cas9 protein, the first guide RNA or the DNA encoding the first guide RNA, and the second guide RNA or the DNA encoding the second guide RNA are each introduced into the population of mouse ES cells by electroporation or nucleofection.

13. The method of claim 1 , wherein step (a)(i) comprises introducing the nucleic acid encoding the Cas9 protein, the first guide RNA, and the second guide RNA into the population of mouse one-cell stage embryos, wherein the nucleic acid encoding the Cas9 protein is RNA, or

wherein the Cas9 protein or the nucleic acid encoding the Cas9 protein, the first guide RNA or the DNA encoding the first guide RNA, and the second guide RNA or the DNA encoding the second guide RNA are introduced into the population of mouse one-cell stage embryos by pronuclear injection or cytoplasmic injection.

14. The method of claim 1 , wherein the method does not comprise introducing an exogenous repair template into the population of mouse one-cell stage embryos or the population of mouse ES cells.

15. The method of claim 1 , wherein:

(I) the introducing step (a)(i) further comprises introducing into the population of mouse one-cell stage embryos an exogenous repair template comprising a 5′ homology arm that hybridizes to a 5′ target sequence at the target genomic locus and a 3′ homology arm that hybridizes to a 3′ target sequence at the target genomic locus, wherein the exogenous repair template is no more than about 5 kb in length; or

(II) the introducing step (a)(i) further comprises introducing into the population of mouse ES cells an exogenous repair template comprising a 5′ homology arm that hybridizes to a 5′ target sequence at the target genomic locus and a 3′ homology arm that hybridizes to a 3′ target sequence at the target genomic locus.

16. The method of claim 15 , wherein the exogenous repair template further comprises a nucleic acid insert flanked by the 5′ homology arm and the 3′ homology arm.

17. The method of claim 1 , wherein the mouse strain is a mix of BALB/c, C57BL/6, and 129 strains.

18. The method of claim 17 , wherein the mouse strain is 50% BALB/c, 25% C57BL/6, and 25% 129.

19. The method of claim 1 , wherein the MHC haplotype of the mouse is MHC b/d .

20. The method of claim 1 , wherein the Cas9 protein has double-strand-break-inducing activity, and wherein paired double-strand breaks are created at different sites within the target genomic locus.

Assignments (1)

Continuity (4)

References Cited (358)